

Imlunestrant for treating oestrogen receptor- positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)

Technology appraisal guidance

Published: 18 June 2026

www.nice.org.uk/guidance/ta1168

Contents

Advice.....	3
What this means in practice.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy in adults. The company has confirmed that it does not intend to make an evidence submission for the evaluation. This is because the technology is unlikely to be a cost-effective use of NHS resources.

NICE will review the position if the company decides that it wants to make an evidence submission.

What this means in practice

Imlunestrant is not required to be funded in the NHS in England for the condition and population stated in this terminated evaluation.

This is because an evidence submission was not provided, so NICE is unable to evaluate whether imlunestrant offers benefit and is value for money in this population.

If NHS organisations wish to consider imlunestrant for this indication, they should follow the advice on local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). These outline the approach that should be taken when there is no NICE guidance.

ISBN: 978-1-4731-9553-0